Tambjamines as Fast-Acting Multistage Antimalarials

ACS Infect Dis. 2024 Dec 13;10(12):4291-4300. doi: 10.1021/acsinfecdis.4c00659. Epub 2024 Nov 11.

Abstract

Well-tolerated and novel antimalarials that can combat multiple stages of the parasite life cycle are desirable but challenging to discover and develop. Herein, we report results for natural product-inspired novel tambjamine antimalarials. We show that they are potent against liver, asexual erythrocytic, and sexual erythrocytic parasite life cycle stages. Notably, our lead candidate 1 (KAR425) displays excellent oral efficacy with complete clearance of parasites within 72 h of treatment in the humanized Plasmodium falciparum (NOD-scid) mouse model at 50 mg/kg × 4 days. Profiling of compound 1 demonstrated a fast in vitro killing profile. In addition, several other tambjamine analogues cured erythrocytic Plasmodium yoelii infections after oral doses of 30 and 50 mg/kg × 4 days in a murine model while exhibiting good safety and metabolic profiles. This study presents the first account of multiple-stage antiplasmodial activities with rapid killing profile in the tambjamine family.

Keywords: antimalarials; antiplasmodial; fast-acting; multistage; natural products; tambjamines.

MeSH terms

  • Animals
  • Antimalarials* / pharmacology
  • Disease Models, Animal
  • Erythrocytes / drug effects
  • Erythrocytes / parasitology
  • Humans
  • Life Cycle Stages / drug effects
  • Malaria* / drug therapy
  • Malaria, Falciparum / drug therapy
  • Malaria, Falciparum / parasitology
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Plasmodium falciparum* / drug effects
  • Plasmodium yoelii / drug effects

Substances

  • Antimalarials